Cell-free DNA is elevated in chronic myeloproliferative neoplasms: correlation with thrombosis and disease progression

GLEMBOTSKY AC; MOIRAGHI B; BENDEK G; VERRI V; LEV PR; MARTA RF; MARIN OYARZUN CP; CASTRO RIOS MA; SACKMANN F; CORTES GUERRIERI V; VALLEJOS V; AYALA D; HELLER PG; DE LUCA G; GUTIERREZ M; VICENTE A ; VARELA A; CAULA V; GOETTE NP; SCHATTNER M

Milán

Congreso; International Society of Thrombosis and Haemostasis ISTH 2020 virtual congres; 2020

International Society of Thrombosis and Haemostasis ISTH

Background: Thrombosis remains the main complication in myeloproliferative neoplasms (MPN). Although age, previous thrombosis and JAK2V617F are associated with thrombotic risk, additional predictive factors are lacking. Cell-free(cf) DNA is associated with thrombosis in diverse prothrombotic conditions and was found elevated in small MPN cohorts. Aims:To assess whether cfDNA is useful as a biomarker for thrombosis and clinical outcome in MPN.Methods:cfDNA was measured by fluorometry using PicoGreen.Results:Circulating cfDNA was elevated in MPN (n=107) vs. controls (P